ArticleActa pharmaceutica Sinica. B2020

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.

Zongru Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.